One of the quiet assumptions many people carry about gout is that "no pain means no problem." A study published in Frontiers in Immunology this month chips away at that assumption. It found that monosodium urate (MSU) crystals — the microscopic needles behind gout — are associated with low-level inflammation in the joint even when a person is between flares or has elevated uric acid without ever having had an attack. The finding does not change how gout is treated, but it reframes what "feeling fine" actually tells you.
What the Study Did
The researchers set out to answer a question that has been hard to study directly: does crystal deposition cause inflammation in the joint even when there is no active flare? To test this, they enrolled 100 participants with either asymptomatic hyperuricemia (high uric acid without gout symptoms) or intercritical gout (gout between attacks), then collected synovial fluid from the joint and analyzed the white blood cell counts and inflammatory protein profiles. Of the 81 samples that could be assessed, a subset contained MSU crystals, another contained calcium pyrophosphate (CPP) crystals, and the rest had no crystals.
The comparison was telling. Samples with MSU crystals had higher leukocyte (white blood cell) counts than samples with CPP crystals or no crystals at all. About a third of the MSU crystals were found inside cells, indicating an active immune response. And a set of inflammatory proteins — including CXCL-1, CXCL-6, and others involved in recruiting immune cells — was upregulated specifically in the MSU-containing samples. The authors concluded that MSU crystal deposition is associated with subclinical inflammation, even when the person is not experiencing a flare.
What "No Pain" Does and Does Not Mean
The practical takeaway is subtle and worth stating carefully. The study does not say everyone with high uric acid is silently damaging their joints, and it is not a call to treat asymptomatic hyperuricemia more aggressively — that is a separate clinical question with its own controversy. What it does suggest is that the absence of a flare is not the same as the absence of crystal activity. Crystals can be present, and can be driving a low-grade inflammatory response, during periods that feel completely normal.
This matters because of how gout progresses. Flares are the loud part of the disease, but the damage — crystal buildup, tophi, progressive joint injury — accumulates in the quiet periods. The study's most useful message for patients is less about alarm and more about the logic of long-term urate management: keeping uric acid low is aimed at dissolving crystals and preventing that silent accumulation, not just at stopping the next flare. Whether and how to treat is a decision for a doctor, not something to self-manage based on a single study.
Why This Connects to Diet
Diet is the part of urate management a person controls daily, and it sits alongside medication rather than replacing it. The foods that consistently move the needle — limiting alcohol (especially beer), moderating red meat and high-purine seafood, cutting sugary drinks that add fructose, and leaning on dairy, vegetables, and hydration — are the same habits that support lower uric acid over months, not just during a flare. The GoutFoodGuide database exists for exactly this: checking the purine and fructose values of individual foods so the daily choices are informed rather than guessed.
For a person with a history of gout, the study adds a quiet argument for consistency. A flare feels like the time to be careful, but the research points the other way — the between-flare period is when the silent crystal accumulation is happening, and that is precisely when the daily habits matter most. It is not about fear; it is about recognizing that "no pain" is not a signal to stop paying attention.
The Limits to Keep in Mind
Like any single study, this one has boundaries. The sample of MSU-positive samples was small — five samples with MSU crystals compared with eleven with CPP and sixty-five with none — so the statistical power is limited and the findings need replication. The study is also correlational at the cellular level: it shows an association between crystals and inflammatory markers, not a proven causal chain that predicts future joint damage. And it says nothing about treatment thresholds, which remain a matter for clinical guidelines and individual doctors. These limits do not undercut the finding; they just place it correctly as an intriguing piece of evidence rather than a clinical mandate.
The same logic extends to medication adherence: if crystals accumulate silently between flares, the value of keeping uric acid consistently low is that it gradually dissolves those deposits, not that it stops the next attack. The study does not change treatment guidance, but it does make the rationale for long-term consistency easier to see.
Frequently Asked Questions
Q: Can you have gout inflammation without a flare?
A: This study suggests yes, at a subclinical level. Samples containing monosodium urate crystals had higher white blood cell counts and elevated inflammatory proteins even in people who were between flares or had no gout symptoms. The inflammation is low-grade and below the threshold of pain, but it appears to be present when crystals are present.
Q: Does high uric acid damage joints even if I have no pain?
A: The short answer is that crystal deposition can continue silently between flares, and this study provides evidence that it is accompanied by low-grade inflammation. However, the study does not prove that everyone with high uric acid is damaging their joints, and it does not change the question of when to treat — that decision remains with a doctor.
Q: What should I do if my uric acid is high but I have no symptoms?
A: The most useful step is to talk with your doctor about your uric acid level and whether monitoring or treatment is appropriate, rather than deciding on your own. Diet and hydration support lower uric acid over the long term, but they are complements to medical advice, not substitutes. The absence of a flare is not a reason to ignore a persistently elevated level.
References: Andrés M, Peral-Garrido ML, et al. Subclinical inflammation associated with monosodium urate crystal deposition: a cellular and proteomic study in synovial fluid. Front Immunol. 2026;17:1888214. frontiersin.org; ACR 2020 Guideline for the Management of Gout.